论文部分内容阅读
恶性肿瘤的转移是癌症患者治疗失败的常见原因。组织蛋白酶参与许多癌细胞的浸润以及肿瘤血管生长过程。若这一过程被抑制,则可能减少肿瘤的转移,延缓肿瘤的发展,改善预后。研究发现Cystatin C通过抑制组织蛋白酶B和L的活性,从而减少肿瘤间质组织以及基底膜的降解,延缓了肿瘤的浸润以及转移过程。因此,Cystatin C有望成为抗肿瘤转移的治疗靶点。
Malignant tumor metastasis is a common cause of treatment failure in cancer patients. Cathepsin is involved in the infiltration of many cancerous cells and in the process of tumor angiogenesis. If this process is inhibited, it may reduce tumor metastasis, delay the development of the tumor and improve the prognosis. Cystatin C has been shown to inhibit tumor invasion and metastasis by inhibiting the activity of cathepsin B and L, thereby reducing the degradation of tumor interstitial tissue and basement membrane. Therefore, Cystatin C is expected to become a therapeutic target for anti-tumor metastasis.